omecamox sodium

Omecamox sodium is a selective relaxant binding agent (SRBA) developed by Zhejiang Xianju Pharmaceutical. It is a modified cyclodextrin derivative designed to rapidly reverse neuromuscular blockade induced by aminosteroid non-depolarizing muscle relaxants, such as rocuronium and vecuronium. The drug works by encapsulating the muscle relaxant molecules in the plasma in a 1:1 ratio, thereby lowering the concentration of free relaxant and facilitating its removal from the neuromuscular junction. This mechanism provides a faster and more reliable recovery from anesthesia compared to traditional acetylcholinesterase inhibitors like neostigmine, and it is specifically intended to avoid the side effects associated with muscarinic receptor activation.

Other names

omecamax sodiumomecamox奥美加莫钠